Lupus patients get continued access to promising drug in new study
NCT ID NCT06875960
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a prior related study. Up to 35 participants will continue the drug to help control their disease. The goal is to keep managing symptoms and prevent flares over the long term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 0001
WITHDRAWNFarmington, Connecticut, 06030, United States
-
Local Institution - 0003
WITHDRAWNJackson, Tennessee, 38305, United States
-
New York University School Of Medicine
RECRUITINGNew York, New York, 10155, United States
Contact Phone: •••-•••-••••
-
Oklahoma Medical Research Foundation
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.